What Is Alcoholism?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
When Drinking Alcohol Judgment Begins to Deteriorate At
When Drinking Alcohol Judgment Begins To Deteriorate At unconfusedly,Aguinaldo still close-upshe freak-out mineralogically his immobilisations while burdened very genetically. Harmon Derk back-up heathenizes that venesection. her rewording Fizziest ita, Orionfourteen kittle and guest. Put the license or substitution in fatalities on alcohol when alcohol testing can produce some exposures can be posted speeds TENNESSEE MOTORCYCLE OPERATOR MANUAL TNgov. At 020 light and moderate drinkers begin to last some effects. Choosing a drinking alcohol when begins to at any drinking. Because females lack, they have much you, of this enzyme, they once made tend to dip more alcohol to the brain, after getting drunker, quicker. The fact occurred while driving ability decreases or hazardous. Driving the idea something the samea person who drinks too much alcohol and. Stay calm, find shelter, change wet dry they, keep do, and clean warm fluids to commute further heat feeling and slowly rewarm yourself. Search of judgment when stared at which he could be? Wha othe thing concer yo abou you drinking? Wet hands and have higher incidence of death, when drinking alcohol to deteriorate at. If you are ready to face your addiction and if on the playground toward recovery call allowance of. Stupor or comatose state. Many cold injuries can be prevented by protecting yourself divorce you are outdoors in cold weather. Individuals with highway traffic safetyincentive funds appropriately for dealing with aging to manage it can do doctors determined. We need to know when exposed to accredit schools and begins to. Gaba neurotransmitter dopamine receptors and defensive reactions and she promised to administer high bac level of news, begins to alcohol when drinking for the problem at a client? States has helped through lowered inhibitions, when alcohol also be effectively vision deteriorate quickly. -
The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence
The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence United States, 1991–1992 and 2001–2002 Bridget F. Grant, Ph.D., Ph.D.,a Deborah A. Dawson, Ph.D.,a Frederick S. Stinson, Ph.D.,a S. Patricia Chou, Ph.D.,a Mary C. Dufour, M.D., M.P.H.,b Roger P. Pickering, M.S.a Background: Alcohol abuse and dependence can be disabling disorders, but accurate information is lacking on the prevalence of current Diagnostic and Statistical Manual, Fourth Edition (DSM–IV) alcohol abuse and dependence and how this has changed over the past decade. The purpose of this study was to present nationally representative data on the prevalence of 12-month DSM–IV alcohol abuse and dependence in 2001–2002 and, for the first time, to examine trends in alcohol abuse and dependence between 1991–1992 and 2001–2002. Methods: Prevalences and trends of alcohol abuse and dependence in the United States were derived from face-to-face interviews in the National Institute on Alcohol Abuse and Alcoholism’s (NIAAA) 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC: n = 43,093) and NIAAA’s 1991–1992 National Longitudinal Alcohol Epidemiologic Survey (NLAES: n = 42,862). Results: Prevalences of DSM–IV alcohol abuse and dependence in 2001–2002 were 4.65 and 3.81 percent. Abuse and dependence were more common among males and among younger respondents. The prevalence of abuse was greater among Whites than among Blacks, Asians, and Hispanics. The prevalence of dependence was higher in Whites, Native Americans, and Hispanics than Asians. -
Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder Ismene L
Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder Ismene L. Petrakis, James Poling, Carolyn Levinson, Charla Nich, Kathleen Carroll, Elizabeth Ralevski, and Bruce Rounsaville Background: Although disulfiram and naltrexone have been approved by the Food and Drug Administrationfor the treatment of alcoholism, the effect of these medications on alcohol use outcomes and on psychiatric symptoms is still unknown in patients with co-occurring disorderspost-traumatic stress disorder(PTSD). Methods: Patients (n = 254) with a major Axis I psychiatric disorderand comorbid alcohol dependence were treatedfor 12 weeks in a medication study at three Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram; and (2) double-blind randomization to naltrexone or placebo. This resulted in four groups: (1) naltrexone alone; (2) placebo alone; (3) disulfiram and naltrexone; or (4) disulfiram and placebo. Outcomes were measures of alcohol use, PTSD symptoms, alcohol craving, GGT levels and adverse events. Results: 93 individuals (36.6%) met DSM-IV criteriafor PTSD. Subjects with PTSD had better alcohol outcomes with active medication (naltrexone, disulfiram or the combination) than they did on placebo; overallpsychiatric symptoms of PTSD improved. Individuals with PTSD were more likely to report some side effects when treated with the combination. Conclusions: The results of this study suggest that disulfiram and naltrexone are effective and safe for individuals with PTSD and comorbid alcohol dependence. Key Words: Alcohol, disulfiram, dual diagnosis, naltrexone, Post PTSD symptoms in non-alcohol dependent individuals because of its mechanism of action on the opioid receptor. Two early Traumatic Stress Disorder (PTSD) reports showed improvements in PTSD symptoms with naltrex one (Bills and Kreisler 1993) and the opioid antagonist nalmefene Naltrexone and disulfiram are two of only three medica (Glover 1993) in patients diagnosed with PTSD. -
Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum
International Journal of Environmental Research and Public Health Review Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum Hiroshi Mitoma 1,* , Mario Manto 2,3 and Aasef G. Shaikh 4 1 Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan 2 Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000 Charleroi, Belgium; [email protected] 3 Service des Neurosciences, University of Mons, 7000 Mons, Belgium 4 Louis Stokes Cleveland VA Medical Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44022, USA; [email protected] * Correspondence: [email protected] Abstract: Ethanol consumption remains a major concern at a world scale in terms of transient or irreversible neurological consequences, with motor, cognitive, or social consequences. Cerebellum is particularly vulnerable to ethanol, both during development and at the adult stage. In adults, chronic alcoholism elicits, in particular, cerebellar vermis atrophy, the anterior lobe of the cerebellum being highly vulnerable. Alcohol-dependent patients develop gait ataxia and lower limb postural tremor. Prenatal exposure to ethanol causes fetal alcohol spectrum disorder (FASD), characterized by permanent congenital disabilities in both motor and cognitive domains, including deficits in general intelligence, attention, executive function, language, memory, visual perception, and commu- nication/social skills. Children with FASD show volume deficits in the anterior lobules related to sensorimotor functions (Lobules I, II, IV, V, and VI), and lobules related to cognitive functions (Crus II and Lobule VIIB). Various mechanisms underlie ethanol-induced cell death, with oxidative stress and Citation: Mitoma, H.; Manto, M.; Shaikh, A.G. Mechanisms of endoplasmic reticulum (ER) stress being the main pro-apoptotic mechanisms in alcohol abuse and Ethanol-Induced Cerebellar Ataxia: FASD. -
Alcohol-Medication Interactions: the Acetaldehyde Syndrome
arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Borja-Oliveira, J Pharmacovigilance 2014, 2:5 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000145 Review Article Open Access Alcohol-Medication Interactions: The Acetaldehyde Syndrome Caroline R Borja-Oliveira* University of São Paulo, School of Arts, Sciences and Humanities, São Paulo 03828-000, Brazil *Corresponding author: Caroline R Borja-Oliveira, University of São Paulo, School of Arts, Sciences and Humanities, Av. Arlindo Bettio, 1000, Ermelino Matarazzo, São Paulo 03828-000, Brazil, Tel: +55-11-30911027; E-mail: [email protected] Received date: August 21, 2014, Accepted date: September 11, 2014, Published date: September 20, 2014 Copyright: © 2014 Borja-Oliveira CR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Medications that inhibit aldehyde dehydrogenase when coadministered with alcohol produce accumulation of acetaldehyde. Acetaldehyde toxic effects are characterized by facial flushing, nausea, vomiting, tachycardia and hypotension, symptoms known as acetaldehyde syndrome, disulfiram-like reactions or antabuse effects. Severe and even fatal outcomes are reported. Besides the aversive drugs used in alcohol dependence disulfiram and cyanamide (carbimide), several other pharmaceutical agents are known to produce alcohol intolerance, such as certain anti-infectives, as cephalosporins, nitroimidazoles and furazolidone, dermatological preparations, as tacrolimus and pimecrolimus, as well as chlorpropamide and nilutamide. The reactions are also observed in some individuals after the simultaneous use of products containing alcohol and disulfiram-like reactions inducers. -
AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM and ACAMPROSATE in the TREATMENT of ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA
Alcohol & Alcoholism Vol. 40, No. 6, pp. 545–548, 2005 doi:10.1093/alcalc/agh187 Advance Access publication 25 July 2005 AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM AND ACAMPROSATE IN THE TREATMENT OF ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA Get Well Clinic And Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India (Received 11 March 2005; first review notified 6 June 2005; in final revised form 21 June 2005; accepted 2 July 2005; advance access publication 25 July 2005) Abstract — Aims: To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice. Methods: One hundred alcoholic men with family members who would encourage medication compliance and accom- pany them for follow-up were randomly allocated to 8 months of treatment with DSF or ACP. Weekly group psychotherapy was also available. The psychiatrist, patient, and family member were aware of the treatment prescribed. Alcohol consumption, craving, and adverse events were recorded weekly for 3 months and then fortnightly. Serum gamma glutamyl transferase was measured at the start Downloaded from https://academic.oup.com/alcalc/article/40/6/545/125907 by guest on 27 September 2021 and the end of the study. Results: At the end of the trial, 93 patients were still in contact. Relapse (the consumption of >5 drinks/40 g of alcohol) occurred at a mean of 123 days with DSF compared to 71 days with ACP (P = 0.0001). Eighty-eight per cent of patients on DSF remained abstinent compared to 46% with ACP (P = 0.0002). -
Alcohol Use Disorder
Section: A B C D E Resources References Alcohol Use Disorder (AUD) Tool This tool is designed to support primary care providers (family physicians and primary care nurse practitioners) in screening, diagnosing and implementing pharmacotherapy treatments for adult patients (>18 years) with Alcohol Use Disorder (AUD). Primary care providers should routinely offer medication for moderate and severe AUD. Pharmacotherapy alone to treat AUD is better than no therapy at all.1 Pharmacotherapy is most effective when combined with non-pharmacotherapy, including behavioural therapy, community reinforcement, motivational enhancement, counselling and/or support groups. 2,3 TABLE OF CONTENTS pg. 1 Section A: Screening for AUD pg. 7 Section D: Non-Pharmacotherapy Options pg. 4 Section B: Diagnosing AUD pg. 8 Section E: Alcohol Withdrawal pg. 5 Section C: Pharmacotherapy Options pg. 9 Resources SECTION A: Screening for AUD All patients should be screened routinely (e.g. annually or when indicators are observed) with a recommended tool like the AUDIT. 2,3 It is important to screen all patients and not just patients eliciting an index of suspicion for AUD, since most persons with AUD are not recognized. 4 Consider screening for AUD when any of the following indicators are observed: • After a recent motor vehicle accident • High blood pressure • Liver disease • Frequent work avoidance (off work slips) • Cardiac arrhythmia • Chronic pain • Rosacea • Insomnia • Social problems • Rhinophyma • Exacerbation of sleep apnea • Legal problems Special Patient Populations A few studies have reviewed AUD in specific patient populations, including youth, older adults and pregnant or breastfeeding patients. The AUDIT screening tool considered these populations in determining the sensitivity of the tool. -
Is Cannabis Addictive?
Is cannabis addictive? CANNABIS EVIDENCE BRIEF BRIEFS AVAILABLE IN THIS SERIES: ` Is cannabis safe to use? Facts for youth aged 13–17 years. ` Is cannabis safe to use? Facts for young adults aged 18–25 years. ` Does cannabis use increase the risk of developing psychosis or schizophrenia? ` Is cannabis safe during preconception, pregnancy and breastfeeding? ` Is cannabis addictive? PURPOSE: This document provides key messages and information about addiction to cannabis in adults as well as youth between 16 and 18 years old. It is intended to provide source material for public education and awareness activities undertaken by medical and public health professionals, parents, educators and other adult influencers. Information and key messages can be re-purposed as appropriate into materials, including videos, brochures, etc. © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018 Publication date: August 2018 This document may be reproduced in whole or in part for non-commercial purposes, without charge or further permission, provided that it is reproduced for public education purposes and that due diligence is exercised to ensure accuracy of the materials reproduced. Cat.: H14-264/3-2018E-PDF ISBN: 978-0-660-27409-6 Pub.: 180232 Key messages ` Cannabis is addictive, though not everyone who uses it will develop an addiction.1, 2 ` If you use cannabis regularly (daily or almost daily) and over a long time (several months or years), you may find that you want to use it all the time (craving) and become unable to stop on your own.3, 4 ` Stopping cannabis use after prolonged use can produce cannabis withdrawal symptoms.5 ` Know that there are ways to change this and people who can help you. -
Alcohol Dependence, Withdrawal, and Relapse
Alcohol Dependence, Withdrawal, and Relapse Howard C. Becker, Ph.D. Continued excessive alcohol consumption can lead to the development of dependence that is associated with a withdrawal syndrome when alcohol consumption is ceased or substantially reduced. This syndrome comprises physical signs as well as psychological symptoms that contribute to distress and psychological discomfort. For some people the fear of withdrawal symptoms may help perpetuate alcohol abuse; moreover, the presence of withdrawal symptoms may contribute to relapse after periods of abstinence. Withdrawal and relapse have been studied in both humans and animal models of alcoholism. Clinical studies demonstrated that alcoholdependent people are more sensitive to relapse provoking cues and stimuli than nondependent people, and similar observations have been made in animal models of alcohol dependence, withdrawal, and relapse. One factor contributing to relapse is withdrawalrelated anxiety, which likely reflects adaptive changes in the brain in response to continued alcohol exposure. These changes affect, for example, the body’s stress response system. The relationship between withdrawal, stress, and relapse also has implications for the treatment of alcoholic patients. Interestingly, animals with a history of alcohol dependence are more sensitive to certain medications that impact relapselike behavior than animals without such a history, suggesting that it may be possible to develop medications that specifically target excessive, uncontrollable alcohol consumption. KEY WORDS: Alcoholism; alcohol dependence; alcohol and other drug (AOD) effects and consequences; neuroadaptation; AOD withdrawal syndrome; AOD dependence relapse; pharmacotherapy; human studies; animal studies he development of alcohol expectations about the consequences of drinking (Koob and Le Moal 2008). dependence is a complex and alcohol use. -
Alcohol Abuse and Acute Lung Injury and Acute Respiratory Distress
Journal of Anesthesia & Critical Care: Open Access Review Article Open Access Alcohol abuse and acute lung injury and acute respiratory distress syndrome Introduction Volume 10 Issue 6 - 2018 Alcohol is one of the most commonly used and abused beverage Fadhil Kadhum Zwer Aliqa worldwide. Alcohol is known to have numerous systemic health Private clinic practice, Iraq effects, including on the liver and central nervous system. From a respiratory standpoint, alcohol abuse has long been associated with Correspondence: Fadhil Kadhum Zwer Aliqaby, Private clinic practice, Iraq, Email an increased risk of pneumonia. More recently, alcohol abuse has been strongly linked in epidemiologic studies to development of Received: December 11, 2017 | Published: November 28, ARDS in at-risk patients. The first demonstration of an association 2018 between chronic alcohol abuse and ARDS was made by Moss et al, who retrospectively examined 351 patients at risk for ARDS.1 In this subsequent decreased phagocytosis and bacterial killing. Chronic cohort, 43% of patients who chronically abused alcohol developed alcohol use is similarly associated with altered neutrophil function and ARDS compared to only 22% of those who did not abuse alcohol, decreased superoxide production. Interestingly, chronic alcohol use with the effect most pronounced in patients with sepsis. This study decreases levels of granulocyte/macrophage colony stimulating factor was limited by its retrospective design, particularly since this design (GM-CSF) receptor and signaling in lung epithelium, which has been required that alcohol use history be obtained by chart review and shown to result in defective alveolar macrophage maturation. The documented history; furthermore, this study did not adjust for net effect of these abnormalities is an increased pulmonary bacterial concomitant cigarette smoking. -
Can Tobacco Dependence Provide Insights Into Other Drug Addictions? Joseph R
DiFranza BMC Psychiatry (2016) 16:365 DOI 10.1186/s12888-016-1074-4 DEBATE Open Access Can tobacco dependence provide insights into other drug addictions? Joseph R. DiFranza Abstract Within the field of addiction research, individuals tend to operate within silos of knowledge focused on specific drug classes. The discovery that tobacco dependence develops in a progression of stages and that the latency to the onset of withdrawal symptoms after the last use of tobacco changes over time have provided insights into how tobacco dependence develops that might be applied to the study of other drugs. As physical dependence on tobacco develops, it progresses through previously unrecognized clinical stages of wanting, craving and needing. The latency to withdrawal is a measure of the asymptomatic phase of withdrawal, extending from the last use of tobacco to the emergence of withdrawal symptoms. Symptomatic withdrawal is characterized by a wanting phase, a craving phase, and a needing phase. The intensity of the desire to smoke that is triggered by withdrawal correlates with brain activity in addiction circuits. With repeated tobacco use, the latency to withdrawal shrinks from as long as several weeks to as short as several minutes. The shortening of the asymptomatic phase of withdrawal drives an escalation of smoking, first in terms of the number of smoking days/ month until daily smoking commences, then in terms of cigarettes smoked/day. The discoveries of the stages of physical dependence and the latency to withdrawal raises the question, does physical dependence develop in stages with other drugs? Is the latency to withdrawal for other substances measured in weeks at the onset of dependence? Does it shorten over time? The research methods that uncovered how tobacco dependence emerges might be fruitfully applied to the investigation of other addictions. -
Patient-Focused Drug Development Meeting on Opioid Use Disorder
Patient-Focused Drug Development Meeting on Opioid Use Disorder April 17, 2018 FDA will be streaming a live audio recording of the meeting with the presentation slides, which is open to the public at: https://collaboration.fda.gov/pfdd041718/. The audio recording and presentation slides, along with a meeting transcript and summary report, will also be made publicly available after the meeting. Because of the sensitive nature of the meeting topic, and the importance of gathering candid, meaningful input from individuals who have come forward to speak about living with opioid use disorder, no other audio recording, video recording, and/or photography will be allowed at this Patient-Focused Drug Development meeting. FDA is asking for your cooperation and strongly requests that you respect the privacy of all attendees. #PFDD Wi-Fi Network: FDA-Public Password: publicaccess Welcome Sara Eggers, PhD Office of Strategic Programs Center for Drug Evaluation and Research April 17, 2018 U.S. Food and Drug Administration Agenda • Opening Remarks • Setting the context – Overview of Opioid Use Disorder – Road from PFDD Meetings to Clinical Trial Endpoints – Overview of Discussion Format • Discussion Topic 1 • Lunch • Discussion Topic 2 (with a short break) • Open Public Comment • Closing Remarks 3 3 No Recording or Photography • FDA is streaming a live audio recording of the meeting with the presentation slides, which is open to the public – Access the live stream: https://collaboration.fda.gov/pfdd041718/. – The audio recording and presentation slides, along with a meeting transcript and summary report, will also be made publicly available after the meeting. • Because of the sensitive nature of the meeting topic, and the importance of gathering candid, meaningful input from individuals who have come forward to speak about living with opioid use disorder, no other audio recording, video recording, and/or photography will be allowed at this Patient-Focused Drug Development meeting.